Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03385655 | Prostate Cancer Biomarker Enrichment and Treatment Selection | active not recruiting | Phase 2 | 200 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 21, 2025 | clinicaltrials |
| NCT04319783 | Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA(DECREASE) | active not recruiting | Phase 2 | 65 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Aug 21, 2025 |
| NCT04015622 | PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA(PROTRACT) | active not recruiting | Phase 2 | 100 | British Columbia Cancer AgencyOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT01990196 | Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer | active not recruiting | Phase 2 | 45 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT00788671 | Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer | active not recruiting | Phase 2 | 69 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06632951 | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)(LIVIGNO-3) | active not recruiting | Phase 2 | 150 | AbbVieINDUSTRY | 8 | Aug 11, 2025 | clinicaltrials |
| NCT06715592 | ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study | active not recruiting | Phase 2 | 18 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT07096583 | An Exploratory Study on NK Cell-assisted Prevention of Bone Marrow Suppression During Chemotherapy for Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 20 | Anhui Provincial Cancer HospitalOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT02768363 | Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES) | active not recruiting | Phase 2 | 187 | Candel Therapeutics, Inc.INDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT05406674 | Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer(CisCon) | active not recruiting | Phase 2 | 40 | The Netherlands Cancer InstituteOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT07047001 | Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma | active not recruiting | Phase 2 | 60 | Dong WenOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT05286294 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders(MITRIC) | active not recruiting | Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT02817958 | Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis(MEGACEP) | active not recruiting | Phase 2 | 37 | UNICANCEROTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT02571725 | PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 50 | New Mexico Cancer Research AllianceOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04575961 | Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer(PERCEPTION) | active not recruiting | Phase 2 | 33 | North Eastern German Society of Gynaecological OncologyOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06383052 | A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC | active not recruiting | Phase 1 / Phase 2 | 30 | Norroy Bioscience Co., LTDINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT04253262 | A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 13 | Brown UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT03689699 | Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | active not recruiting | Phase 1 / Phase 2 | 59 | Mark SteinOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06940921 | SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases | active not recruiting | Phase 1 / Phase 2 | 26 | Zhang TaoOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05340374 | Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer(LuCAB) | active not recruiting | Phase 1 / Phase 2 | 35 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04046094 | Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 12 | University of Kansas Medical CenterOTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04516616 | Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer | active not recruiting | Phase 2 | 85 | Huazhong University of Science and TechnologyOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06884345 | METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer | active not recruiting | Phase 1 / Phase 2 | 28 | Anhui Provincial Cancer HospitalOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT03525288 | PSMA-PET Guided Radiotherapy(PSMA-PETgRT) | active not recruiting | Phase 2 / Phase 3 | 130 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04487587 | A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer(COMICE) | active not recruiting | Phase 2 | 79 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT02202772 | Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder(CGC) | active not recruiting | Phase 1 / Phase 2 | 51 | Guarionex J. DecastroOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT03763253 | Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms(IP2-ATLANTA) | active not recruiting | Phase 2 | 433 | Imperial College LondonOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05032040 | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies | active not recruiting | Phase 2 | 170 | Xencor, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05383079 | Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer(AlphaBet) | active not recruiting | Phase 1 / Phase 2 | 36 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04625270 | A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation(RAMP 201) | active not recruiting | Phase 2 | 225 | Verastem, Inc.INDUSTRY | 7 | Jan 29, 2025 | clinicaltrials |
| NCT04009967 | Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET Scanning(PICT-01) | active not recruiting | Phase 2 | 30 | CHU de Quebec-Universite LavalOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06771596 | Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix(CC11) | active not recruiting | Phase 2 | 43 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05522231 | Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) | active not recruiting | Phase 2 / Phase 3 | 265 | HutchmedINDUSTRY | 1 | Jan 3, 2025 | clinicaltrials |
| NCT03634540 | A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | active not recruiting | Phase 2 | 118 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT02807805 | Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | active not recruiting | Phase 2 | 37 | Mamta ParikhOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04507841 | Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | active not recruiting | Phase 2 | 67 | Tongji HospitalOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT05547061 | A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy | active not recruiting | Phase 1 / Phase 2 | 91 | Cellbion Co., Ltd.INDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT03569241 | PEACE V: Salvage Treatment of OligoRecurrent Nodal Prostate Cancer Metastases(STORM) | active not recruiting | Phase 2 | 196 | University Hospital, GhentOTHER | 6 | Dec 9, 2024 | clinicaltrials |
| NCT04289779 | Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer(ABATE) | active not recruiting | Phase 2 | 46 | Deepak KilariOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04562311 | Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial Carcinoma | active not recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT04713514 | OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC(TEDOVA) | active not recruiting | Phase 2 | 180 | ARCAGY/ GINECO GROUPOTHER | 3 | Dec 2, 2024 | clinicaltrials |
| NCT05652283 | Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | active not recruiting | Phase 2 | 37 | Bai-Rong XiaOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05128487 | A Study of NDI 1150-101 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 106 | Nimbus Saturn, Inc.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT02124421 | HOT: HIPEC in Ovarian Cancer as Initial Treatment(CRS/HIPEC) | active not recruiting | Phase 2 | 32 | Mercy Medical CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02387203 | Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin | active not recruiting | Phase 2 | 80 | Mercy Medical CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT04879563 | Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project(ASCAPE) | active not recruiting | Phase 2 | 500 | Region Örebro CountyOTHER | 4 | Nov 19, 2024 | clinicaltrials |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 / Phase 2 | 141 | 23andMe, Inc.INDUSTRY | 2 | Nov 15, 2024 | clinicaltrials |
| NCT04430192 | Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy(LuTectomy) | active not recruiting | Phase 1 / Phase 2 | 20 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Nov 8, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 21, 2025source: clinicaltrials